Wockhardt exits US generics business, files for liquidation of subsidiaries

The decision follows years of financial losses in the US generics business, including loss of nearly $8 million in FY 2025, Wockhardt said in a BSE filing

Mumbai-headquartered pharmaceutical firm Wockhardt Ltd on Friday said that it has taken the decision to exit the United States (US) generic pharmaceutical segment as part of a broader realignment of its global strategy.

 

The company stated that the move is in line with its “long-term vision to build a differentiated, innovation-driven pharmaceutical enterprise.” The decision follows years of financial losses in the US generics business, including loss of nearly $8 million in FY 2025, it said in a BSE filing.

 

The company further added that it has filed for voluntary liquidation under the US Bankruptcy Code for its wholly owned US subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC. The liquidation is effective from July 11.